Lab Notes: Main Line firm spins off company that will focus on OTC product pipeline

This week's roundup of recent Philadelphia-area life sciences news includes Galera pushing forward with radiation therapy side effect therapy despite FDA setback.

Previous Texas Children’s Hospital picks Houston Methodist Woodlands CEO as new president
Next Health Care Heroes: How Patricia Mook's crisis-era innovation reshapes nursing at Atrium Health and beyond